Current guidelines recommend use of adjuvant imatinib therapy for many patients with gastrointestinal stromal tumours (GISTs); however, its optimal treatment duration is unknown and some patient groups do not benefit from the therapy. We aimed to apply state-of-the-art, interpretable artificial intelligence (ie, predictions or prescription logic that can be easily understood) methods on real-world data to establish which groups of patients with GISTs should receive adjuvant imatinib, its optimal treatment duration, and the benefits conferred by this therapy.

中文翻译：

---

可解释的人工智能优化局部胃肠道间质瘤患者切除术后伊马替尼的使用：一项观察性队列研究


目前的指南建议对许多胃肠道间质瘤 （GIST） 患者使用伊马替尼辅助治疗;然而，其最佳治疗持续时间尚不清楚，一些患者群体无法从该疗法中受益。我们旨在将最先进的、可解释的人工智能（即易于理解的预测或处方逻辑）方法应用于真实世界数据，以确定哪些 GIST 患者群体应该接受伊马替尼辅助治疗、其最佳治疗持续时间以及这种疗法带来的好处。